IP Library › Granted Patent US 10,479,752
Granted Patent B2
US 10,479,752 · App. 14/363,912 · Granted Nov 19, 2019

Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof

Inventor: Jacob Bar-Tana (Jerusalem, IL)
Assignee: SYNDROMEX LTD.
C07C55/02A61K9/10A61K47/38C07B59/001C07C51/02C07C51/09C07C51/41C07C67/32C07C67/347C07C69/34C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,752
App. No.
14/363,912
Granted
Nov 19, 2019
Kind
B2
Abstract

This invention relates to deuterated tetramethyl dioic acids, compositions comprising them and uses thereof in the treatment of Metabolic Syndrome and any diseases, disorders or symptoms associated therewith.

Claims (138)

1. A deuterium enriched composition of a compound of general formula (I), including any salts, esters or anhydrides thereof:

wherein

L is a straight or branched C 8 -C 16 alkylene; optionally interrupted by at least one moiety selected from O, S, NH, C 5 -C 10 cycloalkylene, C 5 -C 10 cycloheteroalkylene, C 6 -C 18 arylene, C 6 -C 18 heteroarylene;

each of R 1 -R 8 is independently selected from H, D, CH 3 and CD 3 ; wherein at least one of R 1 -R 8 is D or CD 3 ; and

the abundance of deuterium at any D- or CD 3 -occupied position in the compound of the composition is substantially greater than the 0.015% natural abundance of deuterium.

2. A deuterium enriched composition according to claim 1 , wherein said compound of general formula (I), including any salts, esters or anhydrides thereof is:

wherein

L is a straight or branched C 8 -C 16 alkylene; optionally interrupted by at least one moiety selected from O, S, NH, C 5 -C 10 cycloalkylene, C 5 -C 10 cycloheteroalkylene, C 6 -C 18 arylene, C 6 -C 18 heteroarylene;

each of R 1 -R 4 is independently H or D;

each of R 5 -R 8 is independently CH 3 or CD 3 ;

wherein when R 1 -R 4 are H, at least one of R 5 -R 8 is CD 3 ; or when R 5 -R 8 are CH 3 , at least one of R 1 -R 4 is D.

3. A deuterium enriched composition according to claim 1 , wherein said compound of general formula (I), including any salts, esters or anhydrides thereof is:

wherein

L is a straight or branched C 8 -C 16 alkylene; optionally interrupted by at least one moiety selected from O, S, NH, C 5 -C 10 cycloalkylene, C 5 -C 10 cycloheteroalkylene, C 6 -C 18 arylene, C 6 -C 18 heteroarylene;

each of R 1 -R 4 is independently CH 3 or CD 3 , and at least one of R 1 -R 4 is CD 3 ; and

each of R 5 -R 8 is independently H.

4. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 1 -R 4 is D.

5. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 5 -R 8 is CD 3 .

6. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 1 -R 4 is CD 3 .

7. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 5 -R 8 is D.

8. A deuterium enriched composition according to claim 1 , wherein, in said compound, L is any one of —(CH 2 ) 10 — and —(CH 2 ) 12 —.

9. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 1 -R 4 is D and at least one of R 5 -R 8 is CD 3 .

10. A deuterium enriched composition according to claim 1 , wherein, in said compound, at least one of R 1 -R 4 is CD 3 and at least one of R 5 -R 8 is D.

11. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 2 = R 3 = R 4

R 5 = R 6 = R 7 = R 8

II

D

CH 3

III

H

CD 3

IV

D

 CD 3 .

12. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 2

R 3 = R 4

R 5 = R 6

R 7 = R 8

V

D

H

CH 3

CH 3

VI

D

H

CD 3

CH 3

VII

D

H

CH 3

CD 3

VIII

D

H

CD 3

CD 3

IX

D

D

CD 3

 CH 3 .

13. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 3

R 2 = R 4

R 5 = R 6

R 7 = R 8

X

D

H

CH 3

CH 3

XI

D

H

CD 3

CH 3

XII

D

H

CD 3

 CD 3 .

14. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 3

R 2 = R 4

R 5 = R 7

R 6 = R 8

XIII

D

H

CH 3

CH 3 .

15. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 2 = R 3 = R 4

R 5 = R 6 = R 7 = R 8

XIV

CD 3

H.

16. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 2

R 3 = R 4

R 5 = R 6

R 7 = R 8

XV

CD 3

CH 3

H

H.

17. A deuterium enriched composition according to claim 1 , wherein said compound is:

Compound

R 1 = R 3

R 2 = R 4

R 5 = R 6

R 7 = R 8

XVI

CD 3

CH 3

H

H.

18. A composition comprising a deuterium enriched composition of a compound according to claim 1 or any salts, esters or anhydrides thereof.

19. A method of treating a disease, condition, symptom or disorder associated with Metabolic Syndrome in a subject, said method comprising administering to said subject an effective amount of at least one deuterium enriched composition as defined in claim 1 .

20. A method according to claim 19 , wherein said disease, condition or disorder associated with Metabolic Syndrome is selected from dyslipidemia, diabetes, obesity, cancer, hypertension and neurodegeneration.

21. A deuterium enriched composition of a compound according to claim 1 , wherein said compound is 2,2,15,15-tetramethyl(D12)-hexadecanedioic acid or any salt, ester or anhydride thereof.

22. A deuterium enriched composition of a compound according to claim 1 , wherein said compound is 2,2,17,17-tetramethyl(D12)-octadecanedioic acid or any salt, ester or anhydride thereof.

23. An isolated deuterium enriched compound of general formula (I):

wherein each of R 1 -R 4 is independently CD 3 and each of R 5 -R 8 is independently hydrogen and L is a straight C 12 alkyl chain, which is 2,2,15,15-tetramethyl(D12)-hexadecanedioic acid or any salt, ester or anhydride thereof.

24. An isolated deuterium enriched compound of general formula (I):

wherein each of R 1 -R 4 is independently CD 3 and each of R 5 -R 8 is independently hydrogen and L is a straight C 14 alkyl chain, which is 2,2,17,17-tetramethyl(D12)-octadecanedioic acid or any salt, ester or anhydride thereof.

25. A deuterium-enriched composition according to claim 1 wherein D at a specified position in the compound indicates at least 50.1% incorporation of deuterium at that position in the composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: BAR-TANA, JACOB
To: SYNDROMEX LTD.
Reel/Frame 033057/0442 →
Continuity (2)
Provisional Application 61568441 · Dec 8, 2011
Related Publication 20140371314A1 · Dec 18, 2014